ギレアード・サイエンスズは2025年第2四半期に予想以上の利益を得て, 株価の低下とインサイダーセールスにもかかわらず,全年指針を上げ,配当を発表した. Gilead Sciences beat earnings expectations in Q2 2025, raised full-year guidance, and declared a dividend, despite insider sales and a stock dip.

2025年第2四半期には,Gilead Sciencesは2.47ドルのEPSと77億ドルの収益で強い利益を報告し,予想を上回り,2025年の全年予測を株当たり8.058.25ドルに上昇させた. In Q2 2025, Gilead Sciences reported strong earnings with $2.47 EPS and $7.77 billion in revenue, exceeding expectations, and raised its 2025 full-year guidance to $8.05–8.25 per share. 同社は,四半期配当額0.79ドルで2.5%の利回りを発表し,CEOのダニエル・パトリック・オデイとヨハンナ・マーシーエの売却を含む,合計1400万ドルの115,146株のインサイダー販売を行った. The company announced a quarterly dividend of $0.79, yielding 2.5%, and saw insider sales totaling 115,146 shares worth $14 million, including sales by CEO Daniel Patrick O’Day and Johanna Mercier. 組織投資家は、スコティア・キャピタル,シュロダー,レベル4管理者サービスの保有権を減少させた. Institutional investors reduced stakes, with Scotia Capital, Schroder, and Level Four Advisory Services trimming holdings. この四半期に11.2%の株価低下にもかかわらず,ギレアードの株価は125.85ドルで取引され,市場総額は156.13億ドルで,コンセンサス"中等買い"の評価を得ました. Despite a 11.2% stock decline during the quarter, Gilead’s shares traded at $125.85, with a market cap of $156.13 billion and a consensus “Moderate Buy” rating.